Merrimack Pharmaceuticals
Merrimack Pharmaceuticals discovers, designs and develops therapies for the treatment of diseases in the areas of autoimmunity and cancer.
Launch date
Employees
Market cap
CAD305m
Enterprise valuation
(CAD28m) (Public information from May 2024)
Share price
$15.13 MACK
Cambridge Massachusetts (HQ)
Financials
Estimates*
USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|
EBITDA | (78.5m) | (63.4m) | (23.9m) | (5.2m) | (2.8m) | (2.6m) | (2.3m) |
Profit | 472m | (40.5m) | (17.3m) | (3.0m) | (2.5m) | (1.5m) | (1.2m) |
EV / EBITDA | -0.6x | 0.1x | -1.1x | -15.2x | -13.8x | -51.2x | -74.8x |
R&D budget | 67.3m | 50.0m | 11.1m | - | 11.1m | 11.1m | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
N/A | $15.0m | Series B | |
N/A | Series B | ||
N/A | $18.3m | Series C | |
$28.0m | Series D | ||
N/A | $28.3m | Series D | |
$65.0m | Series E | ||
N/A | $35.0m | Series F | |
N/A | $2.4m | Grant | |
$77.0m | Growth Equity VC | ||
N/A | N/A | IPO | |
$25.0m | Post IPO Debt | ||
Total Funding | CAD367m |